THE-THINGS-INDUSTRIES
19.9.2023 16:01:33 CEST | Business Wire | Press release
The Things Industries, a global leader in LoRaWAN® Internet of Things (IoT) solutions, has announced 1.5 million devices connected to its robust network server infrastructure, The Things Stack, marking a new milestone in its journey towards operational excellence and product leadership in the LoRaWAN ecosystem. This and more announcements are being celebrated during the flagship event - The Things Conference, organized by The Things Industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230919065625/en/
The Things Industries has reached 1.5 million connected devices to its LoRaWAN Network Server (Graphic: Business Wire)
The company has emerged as a product leader and is widely respected for its operational excellence, uptime, and product completeness. Among its clients and partners are numerous Fortune 500 companies, utility companies, IoT product scale-ups, and a diverse range of system integrators.
This achievement underscores the company's commitment to product leadership and operational excellence in the market of LoRaWAN solution management software, and the ability to scale IoT projects for The Things Industries’ customers and partners. The Things Industries’ LoRaWAN platform is a global product that can be used in every industry vertical.
The recent report by Beecham Research validates the continued growth of LoRaWAN and the adoption across the world. As a global leader in the market of LoRaWAN network management software providers, The Things Industries validates these findings by seeing wide range adoption of the standard on its platform.
The Things Industries serve the market with its leading platform, The Things Stack Cloud, a managed LoRaWAN network server with advanced features and cloud capability that provides industry-leading uptimes with unlimited scalability. With the cloud capability, free and seamless upgrades come included.
The Things Conference, the company's flagship user event, will showcase the broad adoption and usage of the LoRaWAN standard and The Things Stack Cloud platform. The conference will feature over 100 device manufacturers, 110 speakers sharing their IoT experiences, and more than 60 concrete solutions with detailed business cases will be showcased. The Things Conference takes place on 21 and 22 September 2023 from 9 AM to 5 PM Central European Summer Time. The event will be streamed live worldwide.
Wienke Giezeman, CEO of The Things Industries, commented, "The Things Conference is a gathering where we celebrate hard-won successes in the LoRaWAN user space. IoT is a challenging field, and the level of innovation on display is growing every year. I anticipate engaging with the 1,000+ IoT innovators at our event."
About The Things Industries
Founded in 2015, The Things Industries is a leading provider of LoRaWAN IoT solutions, designed to offer secure and efficient connectivity. With a focus on driving efficiency and sustainability, the company estimates that its platform contributes to over $1 billion in efficiency gains for its customers.
For those interested in building IoT solutions based on LoRaWAN, The Things Industries offers a use case selector for product and service recommendations. To get started with the secure LoRaWAN Network Server, visit https://www.thethingsindustries.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919065625/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom